Hanmi Pharmaceutical's GLP-1 Obesity Drug Receives Product Approval

Hanmi Science, the holding company of the Hanmi Pharmaceutical Group, is surging more than 10% in after-hours trading on Oct. 7.


As of 6:10 p.m. on Oct. 7, Hanmi Science was trading at 64,000 won, up 10.15% from its regular-session closing price of 58,100 won.

A view of Hanmi Pharmaceutical. Hanmi Science website.

A view of Hanmi Pharmaceutical. Hanmi Science website.

View original image

Hanmi Science is the operating holding company of the Hanmi Pharmaceutical Group, whose affiliates include Hanmi Pharmaceutical, Online Pharm, and JVM, a company specializing in automated pharmaceutical dispensing systems. Its main sources of revenue include managing affiliates, income from equity stakes, and patent and brand royalties. It also operates healthcare and pharmaceutical distribution businesses.



The stock is believed to be gaining after news broke that Epeoto Injector, a new GLP-1 obesity treatment developed in-house by Hanmi Pharmaceutical, received product approval from the Ministry of Food and Drug Safety. Hanmi Pharmaceutical is preparing to launch the drug with the goal of supplying it in South Korea by the end of the year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing